1. Health

Discuss in my forum

Carol Eustice

EMA Recommends Approval of Biosimilar for Arthritis Drug Remicade

By July 2, 2013

Follow me on:

Two companies that focus on the development of biosimilar products, Celltrion, Inc. and Hospira, Inc., have received backing by the EMA (European Medicines Agency) to produce biosimilar versions of Remicade. The medicines, called Remsima and Inflectra, are the first biosimilar versions of a monoclonal antibody to be recommended for approval.

Remsima and Inflectra are recommended for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, and ulcerative colitis. The price is expected to be 30% cheaper than the price of the original biologic drug. Johnson & Johnson's Remicade has patent protection in most of Europe through February 2015 and in the United States until September 2018. Plus, there could be patent infringement lawsuits in an attempt to block or slow approval of biosimilars.

Related Articles:

Follow Me:

Facebook | Twitter | Message Board | Newsletter

Photo by Robert Byron (iStockphoto)

Comments
July 17, 2013 at 8:02 am
(1) tarek afifi says:

i like that and iwant other biologecal drugs etanerpt &humara mainlt

Leave a Comment

Line and paragraph breaks are automatic. Some HTML allowed: <a href="" title="">, <b>, <i>, <strike>

©2014 About.com. All rights reserved.

We comply with the HONcode standard
for trustworthy health
information: verify here.